These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 31715606)

  • 41. Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer.
    Asano Y; Kashiwagi S; Goto W; Kurata K; Noda S; Takashima T; Onoda N; Tanaka S; Ohsawa M; Hirakawa K
    Br J Surg; 2016 Jun; 103(7):845-54. PubMed ID: 26953091
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.
    Sinn BV; Weber KE; Schmitt WD; Fasching PA; Symmans WF; Blohmer JU; Karn T; Taube ET; Klauschen F; Marmé F; Schem C; Stickeler E; Ataseven B; Huober J; von Minckwitz G; Seliger B; Denkert C; Loibl S
    Breast Cancer Res; 2019 Dec; 21(1):142. PubMed ID: 31829264
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.
    Bai YG; Gao GX; Zhang H; Zhang S; Liu YH; Duan XN; Xu L
    Chin Med J (Engl); 2020 Mar; 133(5):552-560. PubMed ID: 32044815
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.
    Li F; Zhao Y; Wei L; Li S; Liu J
    Cancer Biol Ther; 2018 Aug; 19(8):695-705. PubMed ID: 29621426
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Levels of different subtypes of tumour-infiltrating lymphocytes correlate with each other, with matched circulating lymphocytes, and with survival in breast cancer.
    Verma R; Hanby AM; Horgan K; Verghese ET; Volpato M; Carter CR; Hughes TA
    Breast Cancer Res Treat; 2020 Aug; 183(1):49-59. PubMed ID: 32577938
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.
    Wimberly H; Brown JR; Schalper K; Haack H; Silver MR; Nixon C; Bossuyt V; Pusztai L; Lannin DR; Rimm DL
    Cancer Immunol Res; 2015 Apr; 3(4):326-32. PubMed ID: 25527356
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer.
    Inoue H; Horii R; Ito Y; Iwase T; Ohno S; Akiyama F
    Breast Cancer; 2018 May; 25(3):268-274. PubMed ID: 29185202
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
    JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Automated quantification of stromal tumour infiltrating lymphocytes is associated with prognosis in breast cancer.
    Gonzàlez-Farré M; Gibert J; Santiago-Díaz P; Santos J; García P; Massó J; Bellosillo B; Lloveras B; Albanell J; Vázquez I; Comerma L
    Virchows Arch; 2023 Nov; 483(5):655-663. PubMed ID: 37500796
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of Intratumoural and Stromal Infiltrating Lymphocytes In The Various Subtypes of Breast Carcinoma Patients who have Received Neoadjuvant Chemotherapy.
    Rangan R; Kanetkar SR; Bhosale SJ; Mane DA; Patil NJ; Gudur RA
    Asian Pac J Cancer Prev; 2023 Jul; 24(7):2347-2352. PubMed ID: 37505765
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relevance of tumor-infiltrating lymphocytes in breast cancer.
    Dushyanthen S; Beavis PA; Savas P; Teo ZL; Zhou C; Mansour M; Darcy PK; Loi S
    BMC Med; 2015 Aug; 13():202. PubMed ID: 26300242
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictive value of tumor-infiltrating lymphocytes for response to neoadjuvant chemotherapy and breast cancer prognosis.
    Li X; Tan Q; Li H; Yang X
    J Surg Oncol; 2021 Jan; 123(1):89-95. PubMed ID: 33047336
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer.
    Luen SJ; Savas P; Fox SB; Salgado R; Loi S
    Pathology; 2017 Feb; 49(2):141-155. PubMed ID: 28049579
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modulation of Immune System - Strategy in the Treatment of Breast Cancer.
    Badiu DC; Zgura A; Gales L; Iliescu L; Anghel R; Haineala B
    In Vivo; 2021; 35(5):2889-2894. PubMed ID: 34410983
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic Value of Natural Killer Cells Besides Tumor-Infiltrating Lymphocytes in Breast Cancer Tissues.
    Bouzidi L; Triki H; Charfi S; Kridis WB; Derbel M; Ayadi L; Sellami-Boudawara T; Cherif B
    Clin Breast Cancer; 2021 Dec; 21(6):e738-e747. PubMed ID: 33727019
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Evaluation of tumor-infiltrating lymphocytes in breast cancer: How to use the 2014 international guidelines?].
    Joyon N; Kordahi M; Blanc-Fournier C; Lacroix-Triki M
    Ann Pathol; 2017 Feb; 37(1):127-132. PubMed ID: 28159402
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer.
    Brodsky AS; Xiong J; Yang D; Schorl C; Fenton MA; Graves TA; Sikov WM; Resnick MB; Wang Y
    BMC Cancer; 2016 Apr; 16():274. PubMed ID: 27090210
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis.
    Wang K; Xu J; Zhang T; Xue D
    Oncotarget; 2016 Jul; 7(28):44288-44298. PubMed ID: 27329588
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype.
    Force J; Howie LJ; Abbott SE; Bentley R; Marcom PK; Kimmick G; Westbrook K; Sammons SL; Parks M; Topping DL; Emerson R; Broadwater G; Hyslop T; Blackwell KL; Nair SK
    Clin Breast Cancer; 2018 Oct; 18(5):410-417. PubMed ID: 29615305
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.
    Meisel JL; Zhao J; Suo A; Zhang C; Wei Z; Taylor C; Aneja R; Krishnamurti U; Li Z; Nahta R; O'Regan R; Li X
    Clin Breast Cancer; 2020 Feb; 20(1):19-24. PubMed ID: 31806448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.